Universal Health Services
UHS
$179.43
+2.54%
Universal Health Services operates one of the largest hospital networks in the United States, delivering healthcare through 346 inpatient behavioral health centers, 29 acute care hospitals, and a broad footprint of outpatient and ambulatory facilities, with additional behavioral health exposure in the UK. The company is a dual-engine operator whose acute care segment generates over 55% of revenue while its higher-margin behavioral health division contributes more than 55% of pretax profits, giving it a distinct profile versus pure-play hospital peers and a meaningful moat in psychiatric care capacity. The current investor narrative centers on the strategic pivot into digital behavioral health following shareholder approval of the Talkspace acquisition, balanced against concerns about payer mix, Medicaid and reimbursement pressure, and the stock's sharp year-to-date drawdown despite steady mid-single-digit revenue growth. Recent quarterly results showing revenue up 5.3% year-over-year and diluted EPS of $5.22 have kept the fundamental debate alive, while a wave of neutral-to-hold analyst actions reflects caution about near-term margin trajectory and integration costs.…
UHS
Universal Health Services
$179.43
Related headlines
Investment Opinion: Should I buy UHS Today?
Rating: Hold with a constructive tilt toward accumulation below $165. The core thesis is that UHS is a cheap, cash-generative behavioral health franchise (7.60x forward PE, ~8% FCF yield on $1.115 billion TTM FCF, 20.46% ROE) whose 9.31x trailing multiple already discounts much of the margin-compression fear, but the absence of margin stabilization and a 12-of-17 Hold analyst consensus argue against paying up before Q4 confirms the trend. The $196.71 average target (+12.4% from $174.98) and 'buy' consensus recommendation of 2.4 anchor a modestly positive expected return rather than a compelling one.
Supporting evidence is valuation-led rather than momentum-led. The stock trades at 7.60x forward EPS of $26.15 versus the roughly 15-20x hospital-operator norm and its own 14.72x in Q3 2024 and 17.68x in Q1 2022, with a PEG of 0.255, EV/EBITDA of 7.01x, and P/S of 0.80x all pointing the same direction. Revenue grew 5.3% year-over-year to $4.733 billion in Q3 2026 with steady sequential progression ($4.496B to $4.638B to $4.733B), and Q3 operating cash flow of $636.6 million funded $421.6 million of free cash flow even after $995.8 million of acquisitions and $245.3 million of buybacks. The offset is profitability: operating margin fell to 9.60% from 11.14% in Q2 and 11.19% in Q1, EBITDA margin slipped to 13.63% from 14.75%, and net margin dropped to 6.52% from 7.73%, so the cheap multiple is partly earned.
Three risks could invalidate the thesis: a Q4 print confirming structural rather than transient margin compression, a Medicaid or state reimbursement cut in Nevada (21% of 2025 operating profits), Texas (19%) or California (13%), and Talkspace integration costs running above plan against a thin $168.7 million cash balance and 1.052 current ratio. The rating would upgrade to Buy on evidence of operating margin recovering above 11% or a decisive reclaim of the $196-$198.59 resistance zone, and would downgrade to Sell on a break below the $170-$172 support that opens the $156 low target and the $140.08 52-week low. Net verdict: undervalued relative to its own history and peers on every multiple, but fairly-to-cheaply valued relative to the current, deteriorating earnings trajectory — a value stock awaiting a catalyst, not a momentum stock.
Sign up to view all
UHS 12-Month Price Forecast
UHS presents a classic cheap-for-a-reason setup: the 7.60x forward PE and 0.255 PEG are deeply discounted against both peers and its own history, but three consecutive quarters of margin compression (11.19% to 9.60%) justify much of that discount until proven transient. The $196.71 average target and 2.4 consensus rating imply modest upside, while the wide $156-$250 range and 12 Hold ratings reflect genuine disagreement about whether Q3 was an integration/seasonal dip or structural reimbursement deterioration. The 55% base-case weight reflects that mid-single-digit revenue growth (5.3% year-over-year) and $1.1 billion of free cash flow provide a floor, but the 25% bear-case weight is meaningful given the -5.96% single-day drop on November 19 and the stock's -23.23% one-year return. I would upgrade to bullish on a Q4 operating margin above 11% or a decisive reclaim of $198.59, and downgrade to bearish on a break below $170 that opens the $156 low target and $140.08 52-week low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Universal Health Services's 12-month outlook, with a consensus price target around $195.94 and implied upside of +9.2% versus the current price.
Average Target
$195.94
20 analysts
Implied Upside
+9.2%
vs. current price
Analyst Count
20
covering this stock
Price Range
$156 - $250
Analyst target range
Coverage is broad with 17 analysts, but sentiment is mixed: 7 rate the stock Buy, 12 Hold, and 1 Sell, producing a consensus recommendation of "buy" with a mean rating of 2.4 that leans neutral-to-cautiously-positive. The average target price of $196.71 implies roughly +12.4% upside from the current $174.98, a modest but positive expected return. The consensus is best characterized as cautiously constructive rather than bullish, with the heavy Hold weighting reflecting analyst reluctance to chase a stock with deteriorating near-term momentum.
The target range is wide, from a low of $156.00 (about -10.8% downside) to a high of $250.00 (roughly +42.9% upside), signaling meaningful disagreement about the company's trajectory. The high target likely assumes successful Talkspace integration, margin recovery toward the 11%+ operating levels seen earlier in 2026, and multiple re-rating toward historical norms, while the low target prices in continued margin compression and reimbursement headwinds. Institutional actions show a clear pattern of caution: RBC Capital reiterated Sector Perform on November 11, Wells Fargo maintained Equal Weight on November 2, Baird stayed Neutral on October 29, and Goldman Sachs and Morgan Stanley both held Neutral/Equal Weight in late July, with only Guggenheim (Buy) and Leerink (Outperform) on the bullish side. The wide spread and predominantly neutral stance indicate limited conviction and elevated uncertainty, which typically translates into higher volatility and less efficient price discovery around catalysts such as earnings and acquisition integration updates.
Bulls vs Bears: UHS Investment Factors
The bear case currently has stronger near-term evidence: three consecutive quarters of margin compression (operating margin from 11.19% to 9.60%), a -5.96% single-day breakdown on November 19, and 12 of 17 analysts sitting on Hold. The bull case rests on valuation and cash generation rather than momentum — a 7.60x forward PE, 0.255 PEG, and roughly 8% FCF yield are genuinely cheap for a business with a behavioral health moat and 20.46% ROE. The single most important tension is whether the Q3 margin decline is a transient integration/seasonal dip or the start of structural reimbursement pressure; if margins recover toward the 11%+ levels seen in H1 2026, the valuation gap closes quickly, but if Q4 confirms further compression, the low target of $156 and even the $140.08 52-week low come into play.
Bullish
- Deep value multiple versus history and peers: UHS trades at a trailing PE of 9.31x and forward PE of 7.60x, versus the roughly 15-20x range typical for hospital operators and its own 14.72x in Q3 2024 and 17.68x in Q1 2022. The PEG ratio of 0.255 and EV/EBITDA of 7.01x reinforce that the market is pricing in substantial pessimism relative to a business still earning $26.15 in consensus forward EPS.
- Strong free cash flow and returns: TTM free cash flow of $1.115 billion against a roughly $13.86 billion market cap implies an FCF yield near 8%, while ROE of 20.46% and ROA of 7.65% show efficient capital deployment. Q3 operating cash flow of $636.6 million comfortably funded $421.6 million of free cash flow even as the company spent $995.8 million on acquisitions and $245.3 million on buybacks.
- Behavioral health moat and mix shift: The 346 inpatient behavioral health centers generate over 55% of pretax profits on a minority of revenue, giving UHS a differentiated, higher-margin engine versus pure-play acute care peers. The Talkspace acquisition, approved by shareholders in May 2026, extends this franchise into digital behavioral health and could add a growth vector to an otherwise mid-single-digit revenue story.
- Analyst targets imply double-digit upside: The $196.71 average target implies +12.4% upside from $174.98, with a high target of $250.00 (+42.9%) reflecting a credible re-rating scenario. Seven of 17 analysts rate the stock Buy with a consensus recommendation of 'buy' and a mean rating of 2.4, and the low target of $156.00 is only -10.8% below the current price, a relatively contained downside band.
Bearish
- Sequential margin compression is real: Operating margin fell to 9.60% in Q3 2026 from 11.14% in Q2 and 11.19% in Q1, with operating income dropping to $454.4 million from $516.7 million sequentially. EBITDA margin slipped to 13.63% from 14.75%, and net margin fell to 6.52% from 7.73%, confirming the pressure is operational rather than accounting noise.
- Severe relative underperformance and broken momentum: The stock is down 23.23% over one year and 20.42% year-to-date versus the S&P 500's +8.03%, a relative strength gap of -31.26%. A -5.96% single-day drop on November 19 erased weeks of gains and pushed shares back below the $180 level that had held through October.
- Thin liquidity and heavy acquisition spending: Cash on hand was just $168.7 million against a current ratio of 1.052, while the company deployed $995.8 million on acquisitions in Q3 alone and repaid $859.4 million of debt. Debt-to-equity of 0.757 leaves limited balance-sheet cushion if Talkspace integration costs or reimbursement pressure intensify.
- Analyst conviction is weak: Twelve of 17 analysts rate the stock Hold and only one Sell, with RBC, Wells Fargo, Baird, Goldman Sachs and Morgan Stanley all neutral through late 2026. The wide $156-$250 target range signals genuine disagreement about margin trajectory, and a predominantly neutral stance typically produces inefficient price discovery around catalysts.
UHS Technical Analysis
UHS is in a damaged longer-term downtrend that has only partially repaired, with the stock down 23.23% over the past year and 20.42% year-to-date, a stark underperformance versus the S&P 500's +8.03% one-year return (relative strength of -31.26%). At $174.98, the shares sit at roughly 32.9% of the 52-week range of $140.08 to $246.33, meaning the stock is in the lower third of its annual band despite a strong six-month recovery of +10.89%. This positioning signals a stock that has stabilized off its lows but remains far from reclaiming its highs, leaving it in a technically vulnerable recovery phase rather than a confirmed uptrend.
Short-term momentum has deteriorated sharply and now diverges from the medium-term trend: the stock fell 5.73% over the past month and 1.29% over three months, but the most recent session saw a brutal -5.96% single-day drop from $186.07 to $174.98 on elevated volume of 741,716 shares. That one-day move erased weeks of gains and pushed the price back below the $180 area that had held through October and early November, when the stock peaked near $198.59 on November 5. The divergence is telling: while the 6-month change remains positive at +10.89%, the 1-month and 1-year figures are both negative, suggesting the recent rally was a counter-trend bounce now at risk of failing rather than a durable trend reversal.
Key technical levels are now clearly defined: immediate support sits at the $170-$172 zone (the late-October lows around $172.18), with the 52-week low of $140.08 as the critical floor, while resistance has formed at the $196-$198.59 recent high and the far more distant $246.33 annual peak. A breakdown below $170 would likely retest the $150s and threaten the 52-week low, whereas a reclaim of $198 would signal genuine trend repair. With a beta of 1.108, UHS is about 11% more volatile than the market, and its max drawdown of -42.19% underscores that position sizing and stop discipline matter considerably for holders of this name.
Beta
1.11
1.11x market volatility
Max Drawdown
-42.2%
Largest decline past year
52-Week Range
$140-$246
Price range past year
Annual Return
-20.4%
Cumulative gain past year
| Period | UHS Return | S&P 500 |
|---|---|---|
| 1m | -1.9% | -9.7% |
| 3m | +1.2% | -9.9% |
| 6m | +13.7% | -7.5% |
| 1y | -20.4% | +4.7% |
| ytd | -18.4% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UHS Fundamental Analysis
Revenue is growing steadily but at a decelerating pace: Q3 2026 revenue of $4.733 billion rose 5.3% year-over-year from $4.495 billion in Q3 2025, continuing a multi-quarter expansion from $4.496 billion in Q1 2026 and $4.638 billion in Q2 2026. The sequential cadence shows consistent top-line progression, with acute care services contributing $2.764 billion and behavioral health $1.966 billion in the latest period, meaning the lower-margin acute segment still drives the majority of sales while the higher-margin behavioral business anchors profitability. The growth trajectory is solid but unspectacular for a hospital operator, implying the investment case rests more on margin execution and capital deployment than on accelerating revenue.
Profitability remains healthy but is compressing at the operating line: Q3 2026 net income was $308.7 million with a net margin of 6.52%, down from $358.4 million and a 7.73% margin in Q2 2026 and $348.7 million (7.76%) in Q1 2026. Operating income fell to $454.4 million in Q3 from $516.7 million in Q2, with the operating margin slipping to 9.60% from 11.14%, while the reported gross margin of 9.60% reflects the company's cost-of-revenue presentation rather than a true gross margin (the 90.4% figure in the valuation data uses a different definition). The sequential margin compression is the key watch item, and the Q3 EBITDA of $645.0 million (13.63% margin) versus $684.0 million (14.75%) in Q2 confirms the pressure is real rather than accounting noise.
Balance sheet and cash generation are adequate but not fortress-like: debt-to-equity stands at 0.757, the current ratio is a thin 1.052, and cash on hand was just $168.7 million at quarter-end against $636.6 million of quarterly operating cash flow and $421.6 million of free cash flow. TTM free cash flow of $1.115 billion against a market cap of roughly $13.86 billion implies a healthy FCF yield near 8%, and ROE of 20.46% and ROA of 7.65% demonstrate efficient capital use. However, the company is actively deploying cash into acquisitions ($995.8 million in Q3 alone, largely the Talkspace deal) and buybacks ($245.3 million), while repaying $859.4 million of debt, so liquidity is being managed tightly and external financing capacity remains a relevant consideration.
Quarterly Revenue
$4.7B
2026-09
Revenue YoY Growth
+5.3%
YoY Comparison
Gross Margin
9.6%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UHS Overvalued?
Because UHS is solidly profitable with positive net income, the PE ratio is the appropriate primary metric: the stock trades at a trailing PE of 9.31x and a forward PE of 7.60x, an unusually low absolute level for a healthcare operator. The gap between trailing and forward multiples implies the market expects earnings growth, consistent with consensus EPS estimates of $26.15 for the forward period, and the PEG ratio of 0.255 suggests the stock is priced at a steep discount to its growth rate. On a price-to-sales basis of 0.80x and EV/EBITDA of 7.01x, the valuation looks inexpensive across every metric.
Relative to the medical care facilities industry, UHS screens as a clear value name: a trailing PE of 9.31x and forward PE of 7.60x sit well below the roughly 15-20x range typical for hospital operators, while the EV/EBITDA of 7.01x is modest versus sector norms in the high single to low double digits. The price-to-book of 1.91x and price-to-cash-flow of 7.44x reinforce the discount, and the 0.80x sales multiple is low for a business with 90%+ gross margins on a revenue-equivalent basis. The discount appears partly justified by margin compression, reimbursement risk, and the stock's -23% one-year decline, but the magnitude suggests the market may be over-penalizing a business still generating over $1.1 billion in annual free cash flow.
Historically, UHS has traded in a wide PE band: the trailing PE of 9.31x compares favorably to the 14.72x seen in Q3 2024 and the 17.68x in Q1 2022, and is near the low end of its multi-year range, while the price-to-sales of 0.80x is far below the 2.16x-3.84x readings from 2024-2025 (though those figures reflect different share-count and price bases). The current price-to-book of 1.91x is roughly in line with the 1.68x-2.31x historical band. Trading near the bottom of its own valuation range signals either a genuine value opportunity or lingering fundamental deterioration, and the recent margin softness tilts the interpretation toward caution until profitability stabilizes.
PE
9.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 6x~18x
vs. Industry Avg
18.9x
Industry PE ~18.9x*
EV/EBITDA
7.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the sharp sequential deterioration in profitability and a tight liquidity position. Operating margin fell from 11.19% in Q1 2026 to 11.14% in Q2 and then to 9.60% in Q3, cutting operating income from $516.7 million to $454.4 million quarter-over-quarter, while net margin dropped to 6.52% from 7.73%. Cash on hand of just $168.7 million against a current ratio of 1.052 is thin for a company that spent $995.8 million on acquisitions and $245.3 million on buybacks in Q3 while repaying $859.4 million of debt, and debt-to-equity of 0.757 means external financing capacity matters if Talkspace integration costs run above plan. Revenue concentration adds another layer: acute care still drives over 55% of sales at lower margins, and three states (Nevada 21%, Texas 19%, California 13% of 2025 operating profits) account for the majority of profitability, so a single state's Medicaid or reimbursement decision can move consolidated results. Market and competitive risks stem from a valuation that is cheap but has been cheap for a reason, plus elevated volatility. At a trailing PE of 9.31x versus the 15-20x hospital-operator norm, the discount is partly justified by margin compression and reimbursement risk, but the stock's -23.23% one-year return and -31.26% relative strength gap versus the S&P 500 show the market has been actively de-rating it. Beta of 1.108 means UHS amplifies market moves by roughly 11%, and the recent -5.96% single-day drop on 741,716 shares demonstrates how quickly sentiment can shift; the Talkspace deal adds integration and digital-health competition risk (Teladoc, Amwell, payer-owned platforms) just as investors are focused on near-term costs. The worst-case scenario is a Q4 earnings report that confirms margin compression is structural rather than transient, triggering downgrades from the 12 Hold-rated analysts and a re-test of the $156.00 low target (-10.8%) and potentially the $140.08 52-week low (-19.9% from $174.98). A simultaneous Medicaid reimbursement cut in Texas or Nevada plus Talkspace integration charges above guidance could push the stock toward the $140 area, and in a broader market drawdown the historical max drawdown of -42.19% shows the tail risk is far larger than the current analyst range implies. Position sizing and stop discipline below the $170-$172 support zone are essential given that a break there opens a path to the $150s.
FAQ
The most severe risk is reimbursement and payer mix: Nevada accounts for 21% of 2025 operating profits, Texas 19% and California 13%, so a single state Medicaid rate decision could move consolidated earnings more than any volume trend, and the 9.60% Q3 operating margin leaves little buffer. Second is the margin trajectory itself, with operating margin down from 11.19% to 9.60% and EBITDA margin from 14.75% to 13.63% in one quarter; if Q4 confirms this is structural, the 12 Hold-rated analysts could downgrade and the stock could retest $156.00 and the $140.08 52-week low. Third is balance-sheet and integration risk: cash of just $168.7 million against a 1.052 current ratio, debt-to-equity of 0.757, $995.8 million of Q3 acquisition spend and $859.4 million of debt repayment leave limited slack if Talkspace costs exceed guidance. Fourth is market and competitive risk, where a 1.108 beta amplifies drawdowns (the stock fell -5.96% in a single session on November 19), digital behavioral health entrants such as Teladoc and Amwell compete directly with the new acquisition, and the historical -42.19% max drawdown shows tail risk far exceeds the current analyst range.
The 12-month distribution is 55% base case at $185-$200, 25% bear case at $140-$156 and 20% bull case at $220-$250, centering the expected outcome near the $196.71 analyst average target, or roughly +12.4% from $174.98. The base case assumes forward EPS of $26.15 is broadly achieved on revenue near $21.20 billion within the $20.9-21.5 billion guidance range, operating margin holds in the 9.5-10.5% band, and free cash flow stays near $1.1 billion, allowing the 7.60x forward multiple to prove too pessimistic. The bear case requires Q4 operating margin below 9%, a Medicaid or state reimbursement cut in Nevada or Texas, or Talkspace charges above guidance, pushing shares to the $156.00 low target and potentially the $140.08 52-week low. The bull case requires margin recovery toward 11%+ as integration costs annualize out, plus multiple expansion toward historical norms, which is what the $250.00 high target embeds. The base case is most likely because mid-single-digit revenue growth of 5.3% and roughly 8% FCF yield provide a valuation floor even without a margin rebound.
On every standard metric UHS screens as undervalued: 9.31x trailing PE, 7.60x forward PE, 0.80x price-to-sales, 1.91x price-to-book, 7.44x price-to-cash-flow and 7.01x EV/EBITDA, all well below the roughly 15-20x PE range typical for hospital operators. The discount is also visible against its own history, with the trailing multiple far below the 14.72x of Q3 2024 and 17.68x of Q1 2022, and the 0.255 PEG implies the market is paying almost nothing for expected earnings growth toward $26.15 per share. That said, the cheapness is partly earned: operating margin compressed from 11.19% to 9.60% across 2026 and net margin fell to 6.52% from 7.73%, so the market is pricing in skepticism about the durability of earnings rather than simply mispricing a stable business. The valuation implies investors expect margin pressure to persist and reimbursement risk to remain unresolved; if Q4 disproves that, a re-rating to even 9-10x forward earnings would support the $220-$250 bull range, whereas confirmation of structural decline would justify the $156 low target.
The risk/reward is modestly favorable but not compelling at $174.98: the $196.71 average analyst target implies +12.4% upside, while the $156.00 low target implies -10.8% downside, a roughly 1.1-to-1 ratio that improves materially below $165. The bull case is anchored in hard numbers — 7.60x forward PE, 0.255 PEG, 7.01x EV/EBITDA, $1.115 billion TTM free cash flow and 20.46% ROE — while the bear case is anchored in a real deterioration, with operating margin falling from 11.19% in Q1 to 9.60% in Q3 and operating income dropping from $516.7 million to $454.4 million. Sentiment is lukewarm rather than hostile, with 7 Buy, 12 Hold and 1 Sell ratings and a 2.4 mean recommendation, and the stock's -23.23% one-year return already discounts a lot of bad news. It is a good buy primarily for value-oriented investors with a 12-24 month horizon who size positions for a 1.108 beta and a possible retest of $156, and it becomes a clearly good buy only after Q4 shows operating margin stabilizing above 9.5% or the price falls into the $150s.
UHS is better suited to a long-term hold of at least 12-24 months than to short-term trading, because the thesis depends on a margin inflection that will only be confirmed across two to three quarterly reports rather than a single catalyst. The stock's volatility profile argues against short horizons: beta of 1.108, a -5.96% single-day drop on November 19, a -23.23% one-year return and a -42.19% historical max drawdown mean near-term price action is dominated by sentiment and reimbursement headlines rather than fundamentals. Income seekers should look elsewhere, since the dividend yield is only 0.37% with a 3.4% payout ratio, so total return must come from multiple re-rating and buyback-driven EPS growth (shares outstanding fell from 64.4 million in Q3 2025 to 58.8 million in Q3 2026). Earnings visibility is moderate — 17 analysts with a wide $156-$250 target range and 12 Hold ratings — so a staged entry, accumulating below $165 and adding on confirmation of operating margin above 11%, is more appropriate than a single lump-sum purchase. A minimum 12-month holding period aligns with the base-case timeline for margin stabilization and the $196.71 average target.

